In the BioHarmony Drug Report Database

"Preview" Icon

Flibanserin

Addyi (flibanserin) is a small molecule pharmaceutical. Flibanserin was first approved as Addyi on 2015-08-18. The pharmaceutical is active against 5-hydroxytryptamine receptor 1A and 5-hydroxytryptamine receptor 2A. Addyi’s patents are valid until 2023-05-09 (FDA).

 

Trade Name

 

Addyi
 

Common Name

 

flibanserin
 

ChEMBL ID

 

CHEMBL231068
 

Indication

 

 

Drug Class

 

Serotonin 5-HT2 receptor antagonists

Image (chem structure or protein)

Flibanserin structure rendering